Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXKOW6)

Drug Name

MKC-1106-MT Drug Info

Synonyms

Melanoma vaccine (MART-1/tyrosinase), Mannkind

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting MART-1 melanoma antigen (MLANA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[4]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[5]
Melanoma vaccine (ALVAC)	DM3HIQY	Melanoma	2C30	Discontinued in Phase 2	[6]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[7]
------------------------------------------------------------------------------------

Drug(s) Targeting Tyrosinase (TYR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[8]
Monobenzone	DMVJS2K	Vitiligo	ED63.0	Approved	[8]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[3]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[4]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[5]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[9]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[10]
Benzothiazole analog 1	DMHXFCQ	Albinism	EC23.2	Patented	[11]
Monoamine derivative 2	DMAZ6DI	Albinism	EC23.2	Patented	[11]
Benzimidazole derivative 3	DMY93WG	Albinism	EC23.2	Patented	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01026051) Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma. U.S. National Institutes of Health.
2	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
3	Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
4	National Cancer Institute Drug Dictionary (drug id 685201).
5	An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
6	Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
7	Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
8	Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5.
9	ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
10	Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
11	Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62.